Tailoring Treatment Selection for Various Stages of NSCLC: Optimizing Patient Outcomes

A panel of experts review what an effective multidisciplinary approach for NSCLC management looks like and subspecialties included in multidisciplinary teams.

Experts examine decision-makers in treatment selection and navigate challenges in organizing multidisciplinary team meetings, from institutional to wider practice perspectives.

Experts explore strategies to increase the number of patients benefiting from multidisciplinary team (MDT) collaboration and the factors MDTs consider when deciding between surgical resection and nonsurgical options for early-stage NSCLC.

Specialists examine techniques for assessing pathological complete responses and various methods for response measurement in patients with NSCLC.

Experts discuss the current standard treatment options for patients diagnosed with early-stage NSCLC [non-small cell lung cancer].

Experts review their considerations when adding immunotherapy to both surgical patients and radiation patients with NSCLC.

A panel discusses the role of neoadjuvant therapy in the current treatment approach for early stages of NSCLC.

Experts deliberate on the optimal timing of chemoimmunotherapy and if it should be before or after surgery.

A panel deliberates post-neoadjuvant strategies and data requirements for optimizing immune checkpoint inhibitors in NSCLC neoadjuvant therapy.

Experts discuss changes they foresee in the perioperative approach landscape for patients with NSCLC.

Specialists review specific prognostic factors and biomarkers that help guide treatment selection for patients with metastatic NSCLC (mNSCLC) and discuss if these biomarkers differ from those observed in early-stage NSCLC.

Experts discuss the current standard treatment options for patients diagnosed with metastatic NSCLC (mNSCLC).

Panelists discuss balancing aggressive treatment strategies and maintaining the patient’s quality of life.

Specialists assess the pros and cons of using immunotherapy in managing metastatic non–small cell lung cancer and delve into dosage variations and considerations when choosing different immunotherapy types.

Specialists discuss unmet needs that continue to exist in treating patients with NSCLC despite advances in treatment, and how these impact patient outcomes.

Experts offer concluding insights on unmet needs in NSCLC treatment and the future of patient care.